Compare
bioAffinity Technologies, Inc. vs Absci Corp vs Foxo Technologies Inc. vs OmniAb, Inc.
| Latest fiscal year | bioAffinity Technologies, Inc. BIAF | Absci Corp ABSI | Foxo Technologies Inc. FOXO | OmniAb, Inc. OABI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $6.16M | $2.80M | $16.37M | $18.67M |
| Revenue growth (YoY) | -34.2% | -38.2% | +304.0% | -29.3% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | -171.6% | n/m | -63.1% | -369.5% |
| Net margin | -242.0% | n/m | -75.9% | -347.0% |
| Net income | -$14.91M | -$115.18M | -$12.43M | -$64.78M |
| EPS (Diluted) | -$8.66 | -$0.84 | n/a | -$0.57 |
| Operating cash flow | -$9.33M | -$92.92M | -$3.87M | -$36.45M |
| Free cash flow | -$9.39M | -$94.03M | -$3.93M | -$37.02M |
| Cash & equivalents | $6.45M | $20.02M | $207.5K | $25.52M |
| Total assets | $10.96M | $216.30M | $44.58M | $300.91M |
| Total liabilities | $3.68M | $26.85M | $33.50M | $33.89M |
| Shareholders' equity | $7.28M | $189.45M | $11.14M | $267.03M |
| Return on year-end equity | -204.9% | -60.8% | -111.5% | -24.3% |
| Shares outstanding | 4.50M | n/a | n/a | 144.31M |
Revenue, most recent five fiscal years
| Fiscal year | bioAffinity Technologies, Inc. | Absci Corp | Foxo Technologies Inc. | OmniAb, Inc. |
|---|---|---|---|---|
| Latest | $6.16M Ended 2025-12-31 | $2.80M Ended 2025-12-31 | $16.37M Ended 2025-12-31 | $18.67M Ended 2025-12-31 |
| 1 year earlier | $9.36M Ended 2024-12-31 | $4.53M Ended 2024-12-31 | $4.05M Ended 2024-12-31 | $26.39M Ended 2024-12-31 |
| 2 years earlier | $2.53M Ended 2023-12-31 | $5.72M Ended 2023-12-31 | $145.3K Ended 2023-12-31 | $34.16M Ended 2023-12-31 |
| 3 years earlier | $6.90M Ended 2022-12-31 | $4.53M Ended 2022-12-31 | $511.0K Ended 2022-12-31 | $59.08M Ended 2022-12-31 |
| 4 years earlier | n/a | $4.01M Ended 2021-12-31 | $120.0K Ended 2021-12-31 | $34.75M Ended 2021-12-31 |